Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Cardio-Oncology
Published in:

Open Access 21-11-2024 | Adverse Effects of Cancer Therapy | Case Report

Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis

Authors: Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Kazuya Hosokawa, Shunsuke Katsuki, Taro Mori, Mikiko Hashisako, Yuki Tateishi, Takeshi Iwasaki, Yoshinao Oda, Shintaro Kinugawa, Kohtaro Abe

Published in: Cardio-Oncology | Issue 1/2024

Login to get access

Abstract

The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.
Literature
1.
Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361.CrossRefPubMed
2.
Moslehi J, Lichtman AH, Sharpe AH, et al. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest. 2021;131:e145186.
3.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.CrossRefPubMed
4.
Vansteenkiste J, Wauters E, Reymen B, et al. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019;30:1244–53.CrossRefPubMed
5.
6.
Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447–58.CrossRefPubMed
7.
Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9:e013757.CrossRefPubMedPubMedCentral
8.
9.
Morimoto S, Imanaka-Yoshida K, Hiramitsu S, et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol. 2005;205:460–7.CrossRefPubMed
10.
Hashimoto T, Takahashi K, Ito K, et al. An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report. Int Cancer Conf J. 2024;13:218–22.CrossRefPubMed
11.
Cavalcante L, Chandana S, Lakhani N, et al. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. J Immunother Cancer. 2024;12:e009475.
12.
Nishimura T, Ninomiya K, Nakashima M, et al. Fulminant myocarditis for non-small-cell carcinoma of the lung with nivolumab and ipilimumab plus chemotherapy. Intern Med. 2023;62:1319–22.CrossRefPubMed
13.
Naganuma K, Horita Y, Matsuo K, et al. An autopsy case of late-onset fulminant myocarditis induced by nivolumab in gastric cancer. Intern Med. 2022;61:2867–71.CrossRefPubMedPubMedCentral
14.
Ramayya T, Mitchell JD, Hartupee JC, et al. Delayed diagnosis and recovery of fulminant immune checkpoint inhibitor-associated myocarditis on VA-ECMO support. JACC CardioOncol. 2022;4:722–6.CrossRefPubMedPubMedCentral
15.
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073–126.CrossRefPubMed
16.
Johnson D, Weisleder H, Yuan H and Carrozzi G. Paclitaxel-induced myocarditis presenting as new-onset heart failure. BMJ Case Rep. 2024;17:255646.
17.
Boutros A, Bottini A, Rossi G, et al. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature. ESMO Open. 2023;8:100791.CrossRefPubMedPubMedCentral
18.
Endo Y, Winarski KL, Sajib MS, et al. Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes. Int J Mol Sci. 2023;24:11694.
19.
Power JR, Alexandre J, Choudhary A, et al. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation. 2021;144:1521–3.CrossRefPubMedPubMedCentral
20.
Lehmann LH, Heckmann MB, Bailly G, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148:473–86.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis
Authors
Ryo Izumi
Toru Hashimoto
Hiroshi Kisanuki
Kei Ikuta
Wataru Otsuru
Soshun Asakawa
Shoei Yamamoto
Kayo Misumi
Takeo Fujino
Keisuke Shinohara
Shouji Matsushima
Kazuya Hosokawa
Shunsuke Katsuki
Taro Mori
Mikiko Hashisako
Yuki Tateishi
Takeshi Iwasaki
Yoshinao Oda
Shintaro Kinugawa
Kohtaro Abe
Publication date
21-11-2024
Publisher
BioMed Central
Published in
Cardio-Oncology / Issue 1/2024
Electronic ISSN: 2057-3804
DOI
https://doi.org/10.1186/s40959-024-00288-0

Other articles of this Issue 1/2024

Cardiovascular and venous thromboembolism risks in cancer patients treated with immune checkpoint inhibitors compared to non-users- a multi-center retrospective study

  • Open Access
  • Research

Cancer therapy related cardiac dysfunction as a result of Panitumumab

Reconstitution of peripheral blood T cell receptor β immune repertoire in immune checkpoint inhibitors associated myocarditis

  • Open Access
  • Research

Coronary artery calcium on lung cancer radiation planning CT aids cardiovascular risk assessment

  • Open Access
  • Research

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

  • Open Access
  • Correspondence

Capecitabine-induced-coronary-vasospasm leading to polymorphic ventricular tachycardia and cardiac arrest

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits